Meet some of our researchers
How do leukemic subclones respond to chemotherapy? Hans Beier Ommen uses monitoring techniques to investigate this question.
Iben Lyskjær’s research is focused on finding better ways to identify and treat high-risk kidney cancer patients.
Sarcoma patients and patients with other rare cancers often experience that nobody knows about their disease and they often feel set aside for the more common cancers.